-Rather than acute inflammation, long-standing multiple sclerosis (MS) course is hallmarked by relentless axonal loss and brain atrophy, both with subtle clinical expression and scarcely visible on conventional MRI studies. Brain atrophy imaging has sophisticated methodological requirements, not always practical and accessible to most centers. Corpus callosum (CC) is a major inter-hemispheric white matter bundle, grossly affected by long term MS and easily assessed by MRI. To determine whether a practical imaging method can reliably follow presumed axonal loss in patients with progressive MS, we designed a 5-year prospective open label study, enrolling 128 consecutive patients (75 relapsing-remitting (RR) and 53 secondary-progressive (SP)), on regular immunomodulatory therapy compared to control group, formed by 23 patients with MRI considered normal. On a conventional best mid-saggital T1W, CC index (CCI) was obtained by measuring anterior, medium and posterior segments of CC, normalized to its greatest anteroposterior diameter using an orthogonal semi-automated linear system. CCI was measured at baseline and at least once yearly. Results were plotted intra-individually; baseline values were used as reference. At baseline, CCI was able to distinguish SP patients from RR and controls, and on follow-up, despite some overlap, demonstrated a progressive reduction from baseline on both RR and SP groups compared to controls. From the third year on, difference between SP and RR patients reached statistical significance, which did not correlated with disability measured by EDSS. So, a corpus callosum index proved practical and feasible to longitudinally demonstrate morphometric callosal changes with potential to be used as a tool for long-term follow-up, mostly in SP patients.KEY WORDS: multiple sclerosis, MRI, corpus callosum. Índice de corpo caloso: um instrumento prático para o seguimento a longo prazo de pacientes com esclerose múltiplaRESUMO -Mais do que inflamação aguda, a perda celular e conseqüente atrofia cerebral são os fatos patofisiológicos mais marcantes na fase progressiva da esclerose múltipla (EM). No entanto, correlatos clínicos e de imagem por ressonância magnética (IRM) destes eventos, requerem sofisticada tecnologia, nem sempre prática e quase nunca acessível à maioria dos centros de tratamento. Deste modo, considerando a hipótese de que esta perda celular compromete fibras associativas que compõem o corpo caloso (CC), estrutura facilmente acessível à IRM convencional, nosso grupo elaborou um estudo prospectivo aberto, atualmente com 5 anos de duração, e envolvendo 128 pacientes consecutivos, todos em acompanhamento regular em nosso centro de tratamento para a EM. A aquisição do índice de CC se deu através de um "melhor" corte meio-sagital em estudo convencional de imagem ponderada por T1, utilizando um sistema linear ortogonal semi-automatizado. Este índice foi obtido no início do seguimento e sua evolução foi acompanhada anualmente. A partir do terceiro ano deste seguimento, sua diferença...

Background: Clinical and imaging are required to characterize activity and progression in MS. The parameters for activity are well defined but not those for progression. The ideal aim for long-term treatment is that neither clinical nor imaging signs of disease should be present, and also no brain atrophy. Objectives: To conduct a comparative clinical-imaging study focusing on MRI brain volumetry. Methods: 174 consecutive relapsing-remitting MS patients (McDonald 2001) were studied, focusing on activity and progression. Annual clinical evaluations (relapse rate and EDSS) and MRI data, along with the annualized evolution of the corpus callosum index (CCI), were compared. Results: Out of 174 patients, 148 were considered clinically “stable” based on EDSS. However, 33 (22.2%) out of this group showed annualized reductions in CCI of more than 0.5%, which was the cutoff for defining significant brain atrophy. Conclusions: Among apparently “stable” relapsing-remitting MS patients, 1/5 showed significant brain atrophy over a follow-up period of at least 7 years. We consider it reasonable to suggest that MRI volume sequences should be included in follow-up protocols, so as to provide information on the real treatment response status.

No abstract